Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/32704
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Santoro A. | en |
dc.contributor.author | Holmes F.A. | en |
dc.contributor.author | Koczwara B. | en |
dc.contributor.author | Lind M.J. | en |
dc.contributor.author | Lluch A. | en |
dc.contributor.author | Marques F. | en |
dc.contributor.author | Miles D. | en |
dc.contributor.author | Richardson G.E. | en |
dc.contributor.author | Schaafsma M.R. | en |
dc.contributor.author | Green M.D. | en |
dc.contributor.author | Koelbl H. | en |
dc.contributor.author | Baselga J. | en |
dc.contributor.author | Galid A. | en |
dc.contributor.author | Guillem V. | en |
dc.contributor.author | Gascon P. | en |
dc.contributor.author | Siena S. | en |
dc.contributor.author | Lalisang R.I. | en |
dc.contributor.author | Samonigg H. | en |
dc.contributor.author | Clemens M.R. | en |
dc.contributor.author | Zani V. | en |
dc.contributor.author | Liang B.C. | en |
dc.contributor.author | Renwick J. | en |
dc.contributor.author | Piccart M.J. | en |
dc.contributor.author | Yang B.-B. | en |
dc.contributor.author | Bashir S. | en |
dc.contributor.author | Hill L.R. | en |
dc.contributor.author | Breddy J. | en |
dc.contributor.author | Foote M.A. | en |
dc.contributor.author | Ackland S.P. | en |
dc.contributor.author | Andreesen R. | en |
dc.contributor.author | Bashford J. | en |
dc.contributor.author | Cascinu S. | en |
dc.contributor.author | Cocconi G. | en |
dc.contributor.author | Cocquyt V. | en |
dc.contributor.author | Coleman R.E. | en |
dc.contributor.author | Dunlop D. | en |
dc.contributor.author | Grothey A. | en |
dc.date.accessioned | 2021-05-14T11:05:10Z | en |
dc.date.available | 2021-05-14T11:05:10Z | en |
dc.date.copyright | 2003 | en |
dc.date.created | 20030211 | en |
dc.date.issued | 2012-10-19 | en |
dc.identifier.citation | Annals of Oncology. 14 (1) (pp 29-35), 2003. Date of Publication: 01 Jan 2003. | en |
dc.identifier.issn | 0923-7534 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/32704 | en |
dc.description.abstract | Background: We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support. Patients and Methods: Patients (n = 157) were randomized to receive either a single 6 mg subcutaneous (s.c.) injection of pegfilgrastim or daily 5 mg/kg s.c. injections of filgrastim, after doxorubicin and docetaxel chemotherapy (60 mg/m2 and 75 mg/m2, respectively). Duration of grade 4 neutropenia, depth of neutrophil nadir, incidence of febrile neutropenia, time to neutrophil recovery and safety information were recorded. Result(s): A single 6 mg injection of pegfilgrastim was as effective as daily injections of filgrastim for all efficacy measures for all cycles. The mean duration of grade 4 neutropenia in cycle 1 was 1.8 and 1.6 days for the pegfilgrastim and filgrastim groups, respectively. Results for all efficacy end points in cycles 2-4 were consistent with the results from cycle 1. A trend towards a lower incidence of febrile neutropenia was noted across all cycles with pegfilgrastim compared with filgrastim (13% versus 20%, respectively). A single fixed dose of pegfilgrastim was as safe and well tolerated as standard daily filgrastim. Conclusion(s): A single fixed dose of pegfilgrastim administered once per cycle of chemotherapy was comparable to multiple daily injections of filgrastim in safely providing neutrophil support during myelosuppressive chemotherapy. Pegfilgrastim may have utility in other clinical settings of neutropenia. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom) | en |
dc.title | A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. | en |
dc.type | Article | en |
dc.type.studyortrial | Randomised controlled trial | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/annonc/mdg019 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 12488289 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12488289] | en |
dc.identifier.source | 36150255 | en |
dc.identifier.institution | (Green) Royal Melbourne/Western Hospitals, Melbourne, Vic., Australia (Koelbl) Martin Luther University, Halle-Wittenberg, Germany (Baselga) Hospital Vall d'Hebron, Barcelona, Spain (Galid) Universitaetsklinik Frauenheilkunde, Vienna, Austria (Guillem) Instituto Valenciano de Oncologia, Valencia, Spain (Gascon) Hospital Clinic, Barcelona, Spain (Siena) Ospedale Niguarda Ca' Granda, Milan, Italy (Lalisang) Academisch Ziekenhuis Maastricht, Maastricht, Netherlands (Samonigg) Medizinische Universitaetsklinik, Graz, Austria (Clemens) Krankenanstalt Mutterhaus de Borrow., Trier, Germany (Zani, Liang, Renwick, Yang, Bashir, Hill, Breddy, Foote) Amgen Incorporated, Thousand Oaks, CA, United States (Piccart) Institut Jules Bordet, Brussels, Belgium (Andreesen) Universitaetsklinik Regensburg, Regensburg, Germany (Bashford) Azienda Ospedaliera di Parma, Parma, Italy (Cocquyt) Universitair Ziekenhuis, Gent, Belgium (Coleman) Weston Park Hospital, Sheffield, United Kingdom (Dunlop) Glasgow Royal Infirmary, Glasgow, United Kingdom (Grothey) Martin-Luther Univ. Halle-Wittenberg, Halle an der Saale, Germany (Holmes) Texas Oncology, Houston, TX, United States (Koczwara) Flinders Medical Centre, Bedford Park, SA, Australia (Lind) Princess Royal Hospital, Hull, United Kingdom (Lluch) Hospital Clinico de Valencia, Valencia, Spain (Marques) Hospital Geral de Santo Antonio, Porto, Portugal (Miles) Guy's Hospital, London, United Kingdom (Richardson) Monash Medical Centre, Clayton, Vic, Australia (Santoro) Instituto Clinico Humanitas, Rozzano, Italy (Schaafsma) Medisch Spectrum Twente, Enschede, Netherlands | en |
dc.description.address | M.D. Green, Royal Melbourne Hospital, Dept. of Haematology/Med. Oncology, Grattan Street, Parkville, Vic. 3050, Australia. E-mail: michael.green@mh.org.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2012 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Breast cancer Clinical trial Hemopoietic growth factor Multicenter study Neutropenia | en |
dc.identifier.authoremail | Green M.D.; michael.green@mh.org.au | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.